Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 5;24(1):780.
doi: 10.1186/s12879-024-09679-1.

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

Ee Vien Low  1   2 , Mohan Dass Pathmanathan  3 , Yi Yang Ten  3 , Suresh Kumar Chidambaram  4 , Wee Ric Kim  5 , Wei Jia Lee  5 , Zhi Wei Teh  5 , Maheshwara Rao Appannan  5 , Mastura Ismail  6 , Azah Abdul Samad  7 , Kalaiarasu M Peariasamy  3   8
Affiliations

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

Ee Vien Low et al. BMC Infect Dis. .

Abstract

Background: The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood. The purpose of this study was to assess how nirmatrelvir/ritonavir treatment affected both PCC and health-related quality of life.

Methods: This retrospective cohort study enrolled 2,524 adults aged 18 years and older who were eligible for nirmatrelvir/ritonavir between July 14 to November 14, 2022. All outcomes were observed from the patient's first visit to the primary health clinic, 1 week, 1 month, 3 months, and 6 months after testing positive for COVID-19. The primary outcome was the presence of PCC. Secondary outcomes included the effects on health-related quality of life, such as walking, bathing and dressing, activities, cause adverse emotions or signs that prevent individuals from leading normal lives over a 180-day observation period.

Results: There were no significant differences observed between the nirmatrelvir/ritonavir and those not administered (control group) in terms of PCC symptoms at 3 months (OR 0.71 95% CI 0.31, 1.64) and 6 months (OR 1.30 95% CI 0.76, 2.21). At 3 months, the use of nirmatrelvir/ritonavir was associated with a 26% reduction in symptoms causing negative emotions (OR 0.74 95% CI 0.60, 0.92) and an increased likelihood of symptoms limiting walking (OR 1.58 95% CI 1.10, 2.27). However, there were no significant differences between the nirmatrelvir/ritonavir and the control group in terms of the impact of PCC on health-related quality of life at 6 months.

Conclusions: Our study indicates that the administration of nirmatrelvir/ritonavir does not significantly reduce PCC after 3 months and 6 months in a population with high vaccination coverage.

Keywords: Long COVID; Malaysia; Nirmatrelvir/ritonavir; post-COVID condition.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

The authors declare that they have no conflict of interests.

Figures

Fig. 1
Fig. 1
Cohort Flow
See this image and copyright information in PMC

References

    1. Ministry of Health Malaysia. COVID-19: What is latest situation in Malaysia? 2024 https://data.moh.gov.my/dashboard/covid-19. Accessed 15 Dec 2023.
    1. Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022;18(1):2027160. 10.1080/21645515.2022.2027160 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. Benefits of Getting https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html. Accessed 15 Dec 2023.
    1. Anand R. PM Muhyiddin receives first Covid-19 vaccine as Malaysia kicks off mass innoculation campaign. Straits Time. 2021.
    1. Ministry of Health Malaysia. COVIDNOW: Vaccination Progress 2023. https://covidnow.moh.gov.my/vaccinations/?refresh=1720781109523. Accessed 1 January 2024.

LinkOut - more resources